Gilead sells phase 2 addiction drug to ex-CVT team - FierceBiotech

FierceBiotech
Gilead sells phase 2 addiction drug to ex-CVT team
FierceBiotech
Gilead has sold a phase 2-ready addiction candidate to Amygdala Neurosciences. The deal returns control of the ALDH2 inhibitor to the team that was developing the asset before Gilead acquired it in its $1.4 billion takeover of CV Therapeutics. The 2009 ...
Young startup snags Gilead addiction drug | BioPharma DiveBioPharma Dive
Amygdala Acquires Phase II-Ready Addiction Candidate from GileadGenetic Engineering &